Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 11/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | LSS | P48449 | 1/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.33 |
| ▸ | SLC9A5 | Q14940 | 1/20 | 0.32 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5777281 | 0.91 | HDAC8 (0.34) | HDAC8 | |
| SCHEMBL5776662 | 0.86 | TRPV1 (0.37) | TRPV1HDAC1HDAC2HDAC8 | |
| SCHEMBL5775722 | 0.84 | GSK3B (0.41) | TRPV1HDAC1HDAC2HDAC8FAAH | |
| SCHEMBL5907124 | 0.83 | FAAH (0.36) | TRPV1HDAC1HDAC2HDAC8FAAH | |
| SCHEMBL5772985 | 0.82 | GSK3B (0.41) | TRPV1HDAC1HDAC2HDAC8FAAH | |
| SCHEMBL5775561 | 0.82 | FAAH (0.39) | TRPV1HDAC1HDAC2HDAC8FAAH | |
| SCHEMBL5773874 | 0.81 | MAPT (0.42) | FAAH | |
| SCHEMBL5774897 | 0.81 | MPO (0.35) | HDAC2HDAC8 | |
| SCHEMBL5771107 | 0.80 | HDAC4 (0.35) | TRPV1HDAC1HDAC2HDAC8SLC9A5 | |
| Trifluoroacetic Acid SCHEMBL5774050 | 0.80 | TRPV1 (0.43) | TRPV1HDAC1HDAC2HDAC8FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | TRPV1 2864/4885HDAC1 353/4885HDAC2 449/4885 |
| US-20040048908-A1 | Isoxazole derivatives | GPR119, INSR, IRS1 | TRPV1 3621/4885HDAC1 184/4885HDAC2 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.